Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

  • 01:05

    Myeloma Crowd Radio/MCRI: Dr. Ivan Borrello, MD, Johns Hopkins, Immunotherapy

    in Health

    Dr. Ivan Borrello, MD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, joins us as part of the top 10 projects selected by the Myeloma Crowd Research Initiative. He shares his pioneering work using patients' own immune cells to fight their cancer. His group leads the research for this type of immunotherapy, called adaptive T-cell therapy with MILS (marrow infiltrating lymphocytes). This vaccine is a version for multiple myeloma of those already successful to treat pancreas, prostate and breast cancers. Learn more about this important work in his upcoming study in multiple myeloma.

  • 01:02

    Myeloma Crowd Radio/MCRI: Dr. Robert Orlowski, MD, PhD, Del 17p

    in Health

    The third in our Myeloma Crowd Radio series for the new Myeloma Crowd Research Initiative (MCRI), we talk with Dr. Robert Orlowski, MD, PhD at MD Anderson Cancer Center about work being done specifically for the highest risk multiple myeloma patients with del17p. 


    This is a genetic feature with historically poor outcomes. Learn more about the hypothesis that the biology of del17p could be influenced to introducing genes normally repressed by p53 that would create molecular vulnerabilities and result in new targets to improve outcomes. 


    Special thanks to our Myeloma Crowd Radio episode sponsor, Takeda Oncology. 

  • 01:21

    Myeloma Crowd Radio/MCRI: Dr. Craig Hofmeister, MD, OSU, CAR T cells

    in Health

    Join us for this first interview on Myeloma Crowd Radio highlighting new Myeloma Crowd Research Initiative on high-risk myeloma. For the first time, patients and doctors are joining together to find and fund research for patient group that is desperate for new options. The MCRI initiative reached out the the worldwide community and asked them to submit their research proposals for high-risk patients. We received 36 high quality proposals from all over the world. The MCRI Scientific Advisory Board then scored the proposals, selecting 10 for further review. These ten will be included in the Myeloma Crowd Radio/MCRI series on high-risk.  


    As part of this series, Dr. Craig Hofmeister, MD from Ohio State University will share his research being done to use engineered CAR T cells to specifically target the high-risk types of multiple myeloma. 


    Thanks to our episode sponsor, Takeda Oncology.

  • 01:05

    Myeloma Crowd Radio: Dr. Ravi Vij, MD, Washington University

    in Health

    Are there new treatment options for the relapsed/refractory myeloma patient? Dr. Ravi Vij, MD of Washington University School of Medicine describes some newer approaches and therapies now in clinical trials. 

  • 01:16

    Myeloma Crowd Radio: Dr. Ajay Nooka, MD, MPH, FACP, Emory Winship CI

    in Health

    Can multiple myeloma be cured by shutting it down before it turns from smoldering to active myeloma? Dr. Ajay Nooka of the Emory Winship Cancer Institute joins us to talk about new, early-stage clinical trials being explored for smoldering myeloma patients including a new OncoPep vaccine to prevent progression. 

  • 01:01

    Myeloma Crowd Radio: Dr. Robert Z. Orlowski, MD, PhD MD Anderson Cancer Center

    in Health

    Join us for the first show of 2015 with a review of the ASH conference's most important topics with Dr. Robert Orlowski, MD, PhD, University of Texas MD Anderson Cancer Center. The mPatient Myeloma Radio show change its name to Myeloma Crowd Radio beginning January of 2015. Follow us on Twitter @myelomacrowd or on Facebook at www.facebook.com/myelomacrowd.

  • 01:21

    Myeloma Crowd/MCRI: Dr. Bruno Paiva, PhD, Universidad de Navarra, Flow Cytometry

    in Health

    Join us for our fourth episode of the new Myeloma Crowd Research Initiative of the proposals under consideration for the MCRI patient-led funding initiative. Dr. Bruno Paiva, PhD,  is a multiple myeloma researcher from the University of Navarra Spain specializing in minimal residual disease (MRD) detection using flow cytometry. What does the newer MRD testing mean for high-risk patients? Dr. Paiva will describe his new study to find more clues and therefore better treatments for high-risk patients. 

  • 01:03

    CAR Therapy for Myeloma Treatment with Dr. Craig Hofmeister

    in Health

    CS1-CAR is a new and radically different approach in cancer treatment that harnesses the power of the patients immune system to rid itself of cancer. Initial clinical trials of a similar therapy used in treating Acute Lymphocytic Leukemia showed extraordinary success 88% of patients achieved complete remission. CureTalk panelists are talking to Dr. Craig Hofmeister to help us understand this new therapy and how myeloma patients will benefit.


    MMORE: Multiple Myeloma Opportunities for Research & Education (www.mmore.org) is a non-profit organization that raises funds and awareness for early-stage innovative myeloma research. MMORE spoke about this innovative research on CureTalks in March and we continue the conversation with the researchers in this episode.


    Dr. Craig Hofmeister is assistant professor of medicine at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Dr. Hofmeister received his medical degree from The Ohio State University and completed his internship, residency, and fellowship training at Loyola University Medical Center and Loyola Cardinal Bernardin Cancer Center in Illinois. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Hofmeister's clinical and research interests include multiple myeloma and blood and marrow transplantation. 


    On the panel are Gary Petersen, Pat Killingsworth and Jack Aiello. RSVP Now!


     

  • 01:03

    Allogeneic Transplants for Multiple Myeloma with Dr. Bensinger

    in Health

    March is Myeloma Awareness month and we are exploring the allo transplant therapy route for myeloma patients in our talk with Dr. Bensinger. Why are allogeneic stem cell transplants risky for multiple myeloma patients? When does possible benefit outweigh the risks? RSVP to participate by asking a myeloma question LIVE on the talk to our panel of experts and patients. To mark the Myeloma month of awareness, we have extended our show time by 15 mins where we will have Sarah Kaufmann-Fink of MMore joining us to talk about MMores new research and crowdfunding venture.

  • 01:08

    Pat's Myeloma Beach Party Invite and Interview w/ Dr. Noopur Raje

    in Health

    Its time for Pats Myeloma Beach Party! Hundreds of myeloma patients and caregivers will join Pat Killingsworth this year on Fernandina Beach, Friday afternoon and evening, March 20th, all day on Saturday, March 21st and Sunday for a farewell program and brunch. Dr. Noopur Raje will be at the party this year and talk to the myeloma crowd. Tune in to hear more details on various activities at the party learn more about the Myeloma Crowd Care Foundation, that are dedicated to donating 100% of the money that they raise through crowd funding to sponsor a pair of important, underfunded clinical trials; one to help smoldering myeloma patients and the other to help late stage patients live longer.

  • 01:06

    mPatient Myeloma Radio: Dr. Vincent Rajkumar, MD, Mayo Clinic

    in Health

    The guidelines for myeloma treatment are changing to allow earlier treatment, even without some of the typical symptoms or disease damage. The goal is to treat earlier and prevent severe damage that myeloma causes. Learn more about these new guidelines from Dr. Vincent Rajkumar, MD of the Mayo Clinic on this very important show.

Join Host Live Chats

From the BTR Blog